Mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis: Signals for hope?

Regenerative Medicine

Volumn 9, Issue 5, 2014, Pages 637-647

  Allers, Carolina ^a   Jones, Janet A ^a,b   Lasala, Gabriel P ^a   Minguell, José J ^a  

^a TCA Cellular Therapy   (United States)

^b SOUTHEASTERN LOUISIANA UNIVERSITY   (United States)

Author keywords

ALS; amyotrophic lateral sclerosis; cell based therapy; mesenchymal stem cells; MSC

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL THERAPY; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; TRENDS;

AMYOTROPHIC LATERAL SCLEROSIS; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84908674562     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.30     Document Type: Review

References (97)

1. Janson CG, Ramesh TM, During MJ, Leone P, Heywood J. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J. Hematother. Stem Cell Res. 10(6), 913-915 (2001).
2. NINDS Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/ detail-ALS.htm#244954842
3. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14(4), 248-264 (2013).
4. Nishitoh H, Kadowaki H, Nagai A et al. ALS-linked mutant SOD1 induces ER stress-and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 22(11), 1451-1464 (2008).
5. Seetharaman SV, Prudencio M, Karch C, Holloway SP, Borchelt DR, Hart PJ. Immature copper-zinc superoxide dismutase and familial amyotrophic lateral sclerosis. Exp. Biol. Med. (Maywood) 234(10), 1140-1154 (2009).
6. Fujisawa T, Homma K, Yamaguchi N et al. A novel monoclonal antibody reveals a conformational alteration shared by amyotrophic lateral sclerosis-linked SOD1 mutants. Ann. Neurol. 72(5), 739-749 (2012).
7. Da Cruz S, Cleveland DW. Understanding the role of TDP-43 FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 21(6), 904-919 (2011).
8. Xu ZS. Does a loss of TDP-43 function cause neurodegeneration? Mol. Neurodegener. 7, 27 (2012).
9. Wang Q, Zhang X, Chen S, Zhang S, Youdium M, Le W. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener. Dis. 8(5), 310-321 (2011).
10. Del Aguila MA, Longstreth WT Jr, Mcguire V, Koepsell TD, Van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60(5), 813-819 (2003).
11. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology 63(10), 1933-1935 (2004).
12. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 25(3), 114-119 (2005).
13. Corcia P, Gordon PH. Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Ther. Clin. Risk Manag. 8, 359-366 (2012).
14. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 3, CD001447 (2012).
15. Bova MP, Kinney GG. Emerging drug targets in amyotrophic lateral sclerosis. Expert Opin. Orphan Drugs 1(1), 5-20 (2013).
16. Orrell RW, Lane RJ, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Amyotroph. Lateral Scler. 9(4), 195-211 (2008).
17. Zhang X, Hong YL, Xu DS et al. A review of experimental research on herbal compounds in amyotrophic lateral sclerosis. Phytother. Res. 28(1), 9-21 (2013).
18. Hoffmann M. Linking respiratory chain uncoupling to amyotrophic lateral sclerosis implies potential treatment with herbal extracts containing genipin. Med. Hypotheses 80(3), 327 (2013).
19. Silani V, Cova L, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet 364(9429), 200-202 (2004).
20. Thonhoff JR, Ojeda L, Wu P. Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis. Curr. Stem Cell Res. Ther. 4(3), 178-199 (2009).
21. Lepore AC, O'Donnell J, Kim AS et al. Human glialrestricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS ONE 6(10), e25968 (2011).
22. Hefferan MP, Galik J, Kakinohana O et al. Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS ONE 7(8), e42614 (2012).
23. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun. Signal. 9, 12 (2011).
24. Conget PA, Allers C, Minguell JJ. Identification of a discrete population of human bone marrow-derived mesenchymal cells exhibiting properties of uncommitted progenitors. J. Hematother. Stem Cell Res. 10(6), 749-758 (2001).
25. Delorme B, Ringe J, Pontikoglou C et al. Specific lineagepriming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 27(5), 1142-1151 (2009).
26. Pontikoglou C, Delorme B, Charbord P. Human bone marrow native mesenchymal stem cells. Regen. Med. 3(5), 731-741 (2008).
27. Minguell JJ, Allers C, Lasala GP. Mesenchymal stem cells and the treatment of conditions and diseases: the less glittering side of a conspicuous stem cell for basic research. Stem Cells Dev. 22(2), 193-203 (2013).
28. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp. Mol. Med. 45, e54 (2013).
29. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006).
30. Minguell JJ, Fierro FA, Epunan MJ, Erices AA, Sierralta WD. Nonstimulated human uncommitted mesenchymal stem cells express cell markers of mesenchymal and neural lineages. Stem Cells Dev. 14(4), 408-414 (2005).
31. Rivera FJ, Sierralta WD, Minguell JJ, Aigner L. Adult hippocampus derived soluble factors induce a neuronallike phenotype in mesenchymal stem cells. Neurosci. Lett. 406(1-2), 49-54 (2006).
32. Nagai A, Kim WK, Lee HJ et al. Multilineage potential of stable human mesenchymal stem cell line derived from fetal marrow. PLoS ONE 2(12), e1272 (2007).
33. Fu L, Zhu L, Huang Y, Lee TD, Forman SJ, Shih CC. Derivation of neural stem cells from mesenchymal stem cells: evidence for a bipotential stem cell population. Stem Cells Dev. 17(6), 1109-1121 (2008).
34. Park HE, Kim D, Koh HS, Cho S, Sung JS, Kim JY. Real-time monitoring of neural differentiation of human mesenchymal stem cells by electric cell-substrate impedance sensing. J. Biomed. Biotechnol. 2011, 485173 (2011).
35. Neirinckx V, Coste C, Rogister B, Wislet-Gendebien S. Neural fate of mesenchymal stem cells and neural crest stem cells: which ways to get neurons for cell therapy purpose? In: Trends in Cell Signaling Pathways in Neuronal Fate Decision. Wislet-Gendebien S (Ed.)., InTech, Europe, Croatia, 327-358 (2013).
36. Faca VM. Human mesenchymal stromal cell proteomics: contribution for identification of new markers and targets for medicine intervention. Expert Rev. Proteomics 9(2), 217-230 (2012).
37. Mindaye ST, Ra M, Lo Surdo J, Bauer SR, Alterman MA. Improved proteomic profiling of the cell surface of cultureexpanded human bone marrow multipotent stromal cells. J. Proteomics 78, 1-14 (2013).
38. Wislet-Gendebien S, Hans G, Leprince P, Rigo JM, Moonen G, Rogister B. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 23(3), 392-402 (2005).
39. Montzka K, Lassonczyk N, Tschoke B et al. Neural differentiation potential of human bone marrow-derived mesenchymal stromal cells: misleading marker gene expression. BMC Neurosci. 10, 16 (2009).
40. Hermann A, List C, Habisch HJ et al. Age-dependent neuroectodermal differentiation capacity of human mesenchymal stromal cells: limitations for autologous cell replacement strategies. Cytotherapy 12(1), 17-30 (2010).
41. Niehage C, Steenblock C, Pursche T, Bornhauser M, Corbeil D, Hoflack B. The cell surface proteome of human mesenchymal stromal cells. PLoS ONE 6(5), e20399 (2011).
42. Peng J, Wang Y, Zhang L et al. Human umbilical cord Wharton's jelly-derived mesenchymal stem cells differentiate into a Schwann-cell phenotype and promote neurite outgrowth in vitro. Brain Res. Bull. 84(3), 235-243 (2011).
43. Gu W, Zhang F, Xue Q, Ma Z, Lu P, Yu B. Bone mesenchymal stromal cells stimulate neurite outgrowth of spinal neurons by secreting nuero-trophic factors. Neurol. Res. 34(2), 172-180 (2012).
44. Osathanon T, Manokawinchoke J, Nowwarote N, Aguilar P, Palaga T, Pavasant P. Notch signaling is involved in neurogenic commitment of human periodontal ligament-derived mesenchymal stem cells. Stem Cells Dev. 22(8), 1220-1231 (2013).
45. Kang SK, Lee DH, Bae YC, Kim HK, Baik SY, Jung JS. Improvement of neurological deficits by intracerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats. Exp. Neuol. 183(2), 355-366 (2003).
46. Ding DC, Shyu WC, Chiang MF et al. Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol. Dis. 27(3), 339-353 (2007).
47. Koh SH, Kim KS, Choi MR et al. Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res. 1229, 233-248 (2008).
48. Knippenberg S, Thau N, Dengler R, Brinker T, Petri S. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS ONE 7(6), e36857 (2012).
49. Uccelli A, Milanese M, Principato MC et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol. Med. 18, 794-804 (2012).
50. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J. Neurol. Sci. 189(1-2), 49-57 (2001).
51. Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology 21(1), 82-92 (2001).
52. Zhao CP, Zhang C, Zhou SN et al. Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy 9(5), 414-426 (2007).
53. Satake K, Lou J, Lenke LG. Migration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue. Spine 29(18), 1971-1979 (2004).
54. Bakshi A, Barshinger AL, Swanger SA et al. Lumbar puncture delivery of bone marrow stromal cells in spinal cord contusion: a novel method for minimally invasive cell transplantation. J. Neurotrauma 23(1), 55-65 (2006).
55. Himes BT, Neuhuber B, Coleman C et al. Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord. Neurorehabil. Neural Repair 20(2), 278-296 (2006).
56. Nishida K, Tanaka N, Nakanishi K et al. Magnetic targeting of bone marrow stromal cells into spinal cord: through cerebrospinal fluid. Neuroreport 17(12), 1269-1272 (2006).
57. Vaquero J, Zurita M, Oya S, Santos M. Cell therapy using bone marrow stromal cells in chronic paraplegic rats: systemic or local administration? Neurosci. Lett. 398(1-2), 129-134 (2006).
58. Shi E, Kazui T, Jiang X et al. Intrathecal injection of bone marrow stromal cells attenuates neurologic injury after spinal cord ischemia. Ann. Thorac Surg. 81(6), 2227-2233; discussion 2233-2224 (2006).
59. Lee PH, Lee JE, Kim HS et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann. Neurol. 72(1), 32-40 (2012).
60. Forostyak S, Jendelova P, Kapcalova M, Arboleda D, Sykova E. Mesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis. Cytotherapy 13(9), 1036-1046 (2011).
61. Knippenberg S, Thau N, Dengler R, Brinker T, Petri S. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS ONE 7(6), e36857 (2012).
62. Pastor D, Viso-Leon MC, Jones J et al. Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in a motorneuron degenerative mouse model. Stem Cell Rev. 8(2), 445-458 (2012).
63. Marconi S, Bonaconsa M, Scambi I et al. Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model. Neuroscience 248C, 333-343 (2013).
64. Sun H, Benardais K, Stanslowsky N et al. Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in amyotrophic lateral sclerosis (ALS)-in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia. PLoS ONE 8(9), e72926 (2013).
65. Jaramillo-Merchan J, Jones J, Ivorra JL et al. Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model. Cell Death Dis. 4, e779 (2013).
66. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen. Med. 5(6), 933-946 (2010).
67. Mazzini L, Fagioli F, Boccaletti R et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4(3), 158-161 (2003).
68. Karussis D, Karageorgiou C, Vaknin-Dembinsky A et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67(10), 1187-1194 (2010).
69. Mazzini L, Ferrero I, Luparello V et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp. Neuol. 223(1), 229-237 (2010).
70. Mazzini L, Mareschi K, Ferrero I et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 14(1), 56-60 (2012).
71. Prabhakar S, Marwaha N, Lal V, Sharma RR, Rajan R, Khandelwal N. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study. Neurology India 60(5), 465-469 (2012).
72. Minguell JJ, Allers C, Jones, Ganji SS. Allogeneic mesenchymal stem cells infusion to an ALS patient proved to be safe and capable to initiate clinical recuperation. CellR4 1(3), e530 (2013).
73. ClincalTrials.gov. www.ClinicalTrials.gov.
74. Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant. 40(7), 609-619 (2007).
75. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 25(11), 2896-2902 (2007).
76. Soler B, Fadic R, Von Bernhardi R. [Stem cells therapy in amyotrophic lateral sclerosis treatment. A critical view]. Rev. Neurol. 52(7), 426-434 (2011).
77. Ferrero I, Mazzini L, Rustichelli D et al. Bone marrow mesenchymal stem cells from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant. 17(3), 255-266 (2008).
78. Tichon A, Gowda BK, Slavin S, Gazit A, Priel E. Telomerase activity and expression in adult human mesenchymal stem cells derived from amyotrophic lateral sclerosis individuals. Cytotherapy 11(7), 837-848 (2009).
79. Bossolasco P, Cova L, Calzarossa C et al. Metalloproteinase alterations in the bone marrow of ALS patients. J. Mol. Med. (Berl.) 88(6), 553-564 (2010).
80. Cho GW, Noh MY, Kim HY, Koh SH, Kim KS, Kim SH. Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev. 19(7), 1035-1042 (2010).
81. Nachmany H, Wald S, Abekasis M, Bulvik S, Weil M. Two potential biomarkers identified in mesenchymal stem cells and leukocytes of patients with sporadic amyotrophic lateral sclerosis. Dis. Markers 32(4), 211-220 (2012).
82. Koh SH, Baik W, Noh MY et al. The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate. Exp. Neuol. 233(1), 472-480 (2012).
83. Cramer C, Freisinger E, Jones RK et al. Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells Dev. 19(12), 1875-1884 (2010).
84. Allers C, Lasala GP, Minguell JJ. Presence of osteoclast precursor cells during ex vivo expansion of bone marrowderived mesenchymal stem cells for autologous use in cell therapy. Cytotherapy 16(4), 454-459 (2013).
85. Liu L, Eckert MA, Riazifar H, Kang DK, Agalliu D, Zhao W. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier? Stem Cells Int. 435093 (2013) (2013).
86. Izadpanah R, Kaushal D, Kriedt C et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 68(11), 4229-4238 (2008).
87. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res. Rev. 5(1), 91-116 (2006).
88. Wagner W, Horn P, Castoldi M et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 3(5), e2213 (2008).
89. Madeira A, Da Silva CL, Dos Santos F, Camafeita E, Cabral JM, Sa-Correia I. Human mesenchymal stem cell expression program upon extended ex-vivo cultivation, as revealed by 2-DE-based quantitative proteomics. PLoS ONE 7(8), e43523 (2012).
90. Garbuzova-Davis S, Rodrigues MC, Mirtyl S et al. Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS. PLoS ONE 7(2), e31254 (2012).
91. Lin P, Correa D, Kean TJ, Awadallah A, Dennis JE, Caplan AI. Serial transplantation and long-term engraftment of intraarterially delivered clonally derived mesenchymal stem cells to injured bone marrow. Mol. Ther. 22(1), 160-168 (2013).
92. Riley J, Glass J, Feldman EL et al. Intraspinal stem cell transplantation in ALS: a Phase I trial, cervical microinjection and final surgical safety outcomes. Neurosurgery 74(1), 77-87 (2014).
93. Moviglia GA, Moviglia-Brandolino MT, Varela GS et al. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients. Cell Transplant. 21(Suppl. 1), S57-S63 (2012).
94. Glass JD, Boulis NM, Johe K et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a Phase I trial in 12 patients. Stem Cells 30(6), 1144-1151 (2012).
95. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stemcell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 11(1), 26-34 (2009).
96. Deda H, Inci MC, Kurekci AE et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 11(1), 18-25 (2009).
97. Blanquer M, Moraleda JM, Iniesta F et al. Nuero-trophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells 30(6), 1277-1285 (2012).